ENTOD Pharmaceuticals has teamed up with Infigo Eyecare Hospital, Mumbai, to introduce advanced treatment options for under-eye dark circles and other ocular aesthetic concerns.

This partnership aims to address an often-overlooked aspect of dermatological and ophthalmic care—periorbital health—by integrating progressive innovations into clinical practice.

The skin around the eyes is thinner, more sensitive, and prone to issues like pigmentation, fine lines, and puffiness, yet conventional skincare solutions often fail to deliver precise and lasting results. Current treatments frequently rely on temporary solutions such as topical creams that offer limited absorption and performance.

There is a strong need for breakthroughs in this space to invent specialised, scientifically backed solutions that attend to the root causes of periorbital concerns rather than providing superficial improvements. Nanotechnology has transformed dermatology, boosting treatment efficacy for various skin conditions. It enables deeper penetration of active ingredients, augments bioavailability, and provides sustained release mechanisms, making treatments more impactful.

Periorbital hyperpigmentation (POH) affects a significant portion of the population, with prevalence rates reaching up to 30 percent in India, particularly in individuals with darker skin tones. Genetic predisposition, lifestyle habits, and environmental factors contribute to the condition, often causing distress, particularly among women.

“As a research-driven company, we recognise that while skincare science has refined considerably, under-eye treatments have not kept pace with innovations in dermatology. This joint effort allows us to bring targeted solutions backed by nanotechnology to tackle periorbital concerns effectively. By curating formulations that enhance penetration and provide long-lasting results, we aim to offer solutions that go beyond conventional skincare,” said Nikkhil K Masurkar, CEO of ENTOD Pharmaceuticals.

Infigo Eyecare Hospital, known for its expertise in ophthalmic care, will integrate these developments into its clinical offerings. The collaboration will provide patients access to state-of-the-art treatment protocols designed to mend under-eye pigmentation, reduce puffiness, and promote overall under eye skin health.

“Under-eye aesthetics demand a multi-faceted approach that combines medical expertise with superior formulations. Our goal is to elevate treatment standards by leveraging research-driven solutions. This association ensures that patients receive clinically validated therapies tailored to their specific concerns, bridging the gap between ophthalmology and ocular aesthetic medicine,” said Dr. Shridhar R Thakurat Infigo Eyecare Hospital.

Beyond Mumbai, ENTOD and Infigo Eyecare Hospital plan to expand these specialised treatment options to other cities, making modern under-eye care accessible to a wider population. This initiative highlights the need for increased awareness and research in periorbital health, ensuring that aesthetic treatments evolve to meet growing patient demands successfully.